Cite
HARVARD Citation
Meng, A. et al. (2022). Exposure‐response relationships for the efficacy and safety of filgotinib and its metabolite GS‐829845 in subjects with rheumatoid arthritis based on phase 2 and phase 3 studies. British journal of clinical pharmacology. 88 (7), pp. 3211-3221. [Online].